Stargardt Disease

Stargardt disease is a genetic eye condition that causes progressive loss of central vision. It is the most common inherited macular dystrophy affecting children and young adults. The disease affects the macula, the small central part of the retina responsible for sharp, detailed vision needed for activities like reading, driving, and recognizing faces. While central vision gradually declines, peripheral (side) vision is usually preserved. The condition is caused by a buildup of a fatty waste material called lipofuscin in the cells underlying the retina. Over time, this buildup damages the light-sensitive cells in the eye. Symptoms often begin in childhood or adolescence and include blurry or distorted vision, difficulty seeing in low light, and sometimes problems with color vision. Currently, there is no cure for Stargardt disease, but research into gene therapies and other treatments is ongoing. Patients are advised to wear sunglasses with UV protection to avoid excessive light exposure, which can worsen the condition, and to avoid taking vitamin A supplements, as extra vitamin A can accelerate the buildup of toxic byproducts in the eye. Low vision aids and rehabilitation can help individuals maximize their remaining sight and maintain independence.

Condition category: Macular Dystrophy

Prevalence: 1 in 8,000-10,000

Inheritance patterns: Autosomal Recessive, Autosomal Dominant

Age of onset: Typically late childhood to early adulthood, though late-onset forms (>45 years) exist.

Clinical overview: Stargardt disease, also known as Stargardt macular dystrophy or fundus flavimaculatus, is the most common recessively inherited childhood macular dystrophy. It is characterized by progressive central vision loss, macular atrophy, and the presence of yellowish-white pisciform (fish-tail) flecks at the level of the retinal pigment epithelium (RPE). The condition primarily affects the macula, the central area of the retina responsible for sharp, detailed vision. The classic form of the disease, Stargardt disease type 1 (STGD1; OMIM #248200), is caused by biallelic mutations in the ABCA4 gene. Stargardt-like phenotypes with autosomal dominant inheritance are associated with mutations in ELOVL4 (STGD3; OMIM #600110) and PROM1 (STGD4; OMIM #603786). The Orphanet number for Stargardt disease is ORPHA827. Clinically, the disease presents with significant phenotypic heterogeneity, varying widely in age of onset, severity, and rate of progression. While early-onset cases typically progress more rapidly to severe visual impairment, late-onset forms may have a milder course. The accumulation of lipofuscin in the RPE is a hallmark of the disease, leading to secondary photoreceptor death and the characteristic clinical findings.

Patient and family guide: Stargardt disease is a genetic eye condition that causes progressive loss of central vision. It is the most common inherited macular dystrophy affecting children and young adults. The disease affects the macula, the small central part of the retina responsible for sharp, detailed vision needed for activities like reading, driving, and recognizing faces. While central vision gradually declines, peripheral (side) vision is usually preserved. The condition is caused by a buildup of a fatty waste material called lipofuscin in the cells underlying the retina. Over time, this buildup damages the light-sensitive cells in the eye. Symptoms often begin in childhood or adolescence and include blurry or distorted vision, difficulty seeing in low light, and sometimes problems with color vision. Currently, there is no cure for Stargardt disease, but research into gene therapies and other treatments is ongoing. Patients are advised to wear sunglasses with UV protection to avoid excessive light exposure, which can worsen the condition, and to avoid taking vitamin A supplements, as extra vitamin A can accelerate the buildup of toxic byproducts in the eye. Low vision aids and rehabilitation can help individuals maximize their remaining sight and maintain independence.

Symptoms and clinical features: Patients with Stargardt disease typically present with progressive, painless, bilateral central vision loss. Initial symptoms often include blurry or distorted central vision, difficulty reading, and central scotomas (blind spots). Patients may also experience delayed dark adaptation, photophobia (light sensitivity), and dyschromatopsia (abnormal color vision). In the early stages, visual acuity may be near normal, and the fundus may appear relatively unremarkable, which can delay diagnosis. As the disease progresses to the intermediate stage, visual acuity declines, and the characteristic yellowish-white pisciform flecks become apparent in the macula and mid-periphery. The macula may develop a "beaten bronze" appearance due to lipofuscin accumulation and early atrophic changes. In advanced stages, patients typically experience severe central vision loss, often reaching 20/200 to 20/400, resulting in legal blindness. Extensive chorioretinal atrophy develops in the macula, and the flecks may fade or be replaced by areas of atrophy. Despite the severe loss of central vision, peripheral vision is usually preserved throughout the patient's life.

Molecular pathology: Stargardt disease is primarily caused by mutations in the ABCA4 gene, which encodes the ATP-binding cassette transporter, alpha 4 subunit (ABCA4), also known as the rim protein (RmP). This transmembrane protein is localized to the rim of the disc membranes in the outer segments of rod and cone photoreceptors. Its normal function is to act as a flippase, actively transporting the retinal byproduct N-retinylidene-phosphatidylethanolamine (N-retinylidene-PE) out of the photoreceptor discs during the visual cycle. When ABCA4 is mutated and dysfunctional, N-retinylidene-PE and all-trans-retinal accumulate within the photoreceptor discs. These compounds react to form toxic bisretinoids, primarily A2E (N-retinylidene-N-retinyl-ethanolamine). As the retinal pigment epithelium (RPE) phagocytoses the shed photoreceptor outer segments, A2E accumulates in the RPE cells as a major component of lipofuscin. Lipofuscin is resistant to lysosomal degradation and its progressive accumulation is toxic to the RPE. It impairs RPE metabolic functions and, in the presence of light and oxygen, generates free radicals that induce RPE cell death. The loss of RPE cells, which provide essential nutritional and structural support to photoreceptors, inevitably leads to secondary photoreceptor degeneration and subsequent vision loss.

Genetics: Stargardt disease type 1 (STGD1) is inherited in an autosomal recessive pattern and is caused by mutations in the ABCA4 gene, located on chromosome 1p22.1. The ABCA4 gene exhibits extraordinary allelic heterogeneity, with over 2,000 disease-associated variants discovered, mostly missense mutations. The severity of the disease is generally inversely proportional to the residual ABCA4 activity. Stargardt-like macular dystrophies, which present with overlapping clinical features but are inherited in an autosomal dominant pattern, are caused by mutations in other genes. STGD3 is caused by mutations in the ELOVL4 gene (6q14.1), while STGD4 is caused by mutations in the PROM1 gene (4p15.32). Genotype-phenotype correlations indicate that patients with early childhood onset typically have a more severe phenotype and rapid progression, often associated with nonsense mutations or severe loss of ABCA4 function. Conversely, late-onset disease is usually associated with milder missense mutations that allow for some residual protein function.

Diagnostic evaluation: Diagnosis is based on clinical presentation and multimodal imaging. Fundoscopy typically reveals yellowish-white pisciform (fish-tail) flecks at the level of the RPE, which may extend to the mid-periphery, along with macular atrophy and a characteristic "beaten bronze" appearance. A classic finding on fluorescein angiography is the "dark choroid" or "silent choroid," seen in up to 80% of cases, caused by lipofuscin-laden RPE cells blocking choroidal fluorescence. Optical coherence tomography (OCT) is crucial for demonstrating ellipsoid zone disruption, photoreceptor layer disorganization, and outer retinal loss in the macula. Fundus autofluorescence (FAF) typically shows a central reduction in autofluorescence surrounded by a ring of hyperautofluorescence, creating a bull's eye maculopathy appearance. Full-field electroretinography (ffERG) may be normal in early stages but can show subnormal scotopic and photopic responses as the disease progresses. Genetic testing is essential to confirm the diagnosis and identify specific mutations, most commonly in the ABCA4 gene. Differential diagnosis includes other inherited macular dystrophies, such as Best disease, pattern dystrophies, and cone-rod dystrophies, as well as Stargardt-like dystrophies caused by mutations in ELOVL4 or PROM1.

Differential diagnosis: Differential diagnosis of Stargardt disease includes: (1) Best vitelliform macular dystrophy — vitelliform lesion, abnormal EOG, BEST1 mutations. (2) Pattern dystrophy — butterfly-shaped or reticular pigment changes; PRPH2 mutations. (3) Cone dystrophy — diffuse cone dysfunction on ERG without characteristic flecks. (4) Central areolar choroidal dystrophy — well-defined geographic atrophy without flecks. (5) Fundus flavimaculatus (late-onset Stargardt) — later onset, more peripheral flecks, slower progression. (6) Age-related macular degeneration — older onset (>50 years), drusen rather than flecks, no dark choroid on fluorescein angiography. (7) North Carolina macular dystrophy — nonprogressive, present from birth, PRDM13/MCDR1 mutations. (8) Hydroxychloroquine toxicity — medication history, bull's-eye maculopathy pattern. (9) Sorsby fundus dystrophy — later onset, drusen-like deposits, TIMP3 mutations.

Natural history: The natural history of Stargardt disease is characterized by progressive, bilateral central vision loss. The age of onset is highly variable, most commonly occurring in late childhood or early adolescence, but late-onset forms presenting after age 45 also exist. Disease progression is generally slow but relentless. Patients with early-onset disease tend to experience a more rapid decline in visual acuity and more severe overall retinal degeneration. Conversely, late-onset disease is typically associated with a milder phenotype and slower progression. Over time, the macular atrophy expands, and visual acuity progressively worsens, often stabilizing between 20/200 and 20/400.

Management and treatment research: ### Current management and supportive care There is currently no cure for Stargardt disease. Care focuses on monitoring retinal health, preserving independence, and making the most of remaining vision with an inherited retinal disease specialist. - **Low-vision rehabilitation** can help people use remaining vision more effectively. This may include magnifiers, high-contrast materials, screen-reading software, lighting adjustments, orientation and mobility training, and school or workplace accommodations. - **Regular eye examinations and retinal imaging** help monitor changes in the macula, the central part of the retina responsible for detailed vision. Imaging may also help determine eligibility for research studies. - Many clinicians recommend **protecting the eyes from bright sunlight** with UV-blocking sunglasses and a brimmed hat. Tinted lenses or filters may improve comfort for people with light sensitivity. - People with **ABCA4-associated Stargardt disease** are generally advised to avoid high-dose vitamin A supplements unless their retinal specialist specifically recommends them. Vitamin A contributes to formation of lipofuscin, a retinal deposit that can include the potentially harmful compound A2E. Discuss vitamins, retinoid-containing medicines, and major dietary changes with the treating specialist. ### Approved therapies There are **no FDA-approved treatments specifically for Stargardt disease**. ### Investigational therapies #### Gene and RNA-based approaches Most Stargardt disease is associated with changes in the **ABCA4** gene. Because the ABCA4 gene is too large for a standard adeno-associated virus (AAV) gene-therapy vector, several approaches are being developed to address this challenge. - **OCU410ST** is a Phase 2/3 modifier gene-therapy study (NCT06387200). It uses an AAV5 vector to deliver the **RORA** gene. Rather than replacing ABCA4, this gene-agnostic approach is intended to influence pathways involved in retinal-cell survival. - **Dual-vector or oversized-AAV ABCA4 therapies** are in early Phase 1/2 development (NCT06942572). These approaches aim to deliver the large ABCA4 gene in multiple pieces or through specialized vectors. - **VG801** is a recruiting Phase 1/2 study (NCT07002398). It uses mRNA trans-splicing, an approach intended to enable production of full-length ABCA4 protein after an intravitreal injection, meaning an injection into the gel-like fluid of the eye. - **ACDN-01** is a recruiting Phase 1/2 RNA-editing study (NCT06467344). It is designed to correct certain ABCA4 messenger RNA splicing defects that can interfere with normal ABCA4 protein production. - **AAVB-039** is being evaluated in a recruiting Phase 1/2 study for Stargardt disease (NCT07161544). Early-phase studies primarily assess safety and appropriate dosing. #### Medicines intended to reduce harmful retinal byproducts or support ABCA4 function - **Gildeuretinol (ALK-001)** is being studied in a recruiting Phase 3 trial (NCT07419334). It is an oral modified vitamin A compound designed to slow formation of toxic vitamin A dimers, including A2E, and lipofuscin in the retina. - **Tinlarebant** completed a Phase 3 study (NCT05244304). This oral retinol-binding protein 4 (RBP4) antagonist is intended to reduce delivery of vitamin A to the retina and thereby reduce bisretinoid buildup. - **Metformin** is being studied in an active, not recruiting Phase 1/2 trial for ABCA4 retinopathy (NCT04545736). Researchers are evaluating whether it can promote “read-through” of certain premature stop mutations, potentially allowing some ABCA4 protein to be produced. - A first-in-human study of **CITY-RBP4** is recruiting healthy volunteers and people with STGD1 (NCT07836452). #### Vision-restoration approaches - **MCO-010**, an optogenetic treatment, completed the Phase 2 STARLIGHT study in Stargardt disease (NCT05417126). Optogenetics uses a gene-delivered light-sensitive protein to help surviving retinal cells respond to light. - The **PRIMA System** is a wireless photovoltaic subretinal implant in active, not recruiting follow-up (NCT04676854). It converts projected infrared light patterns into electrical stimulation of remaining retinal neurons and is intended to support central vision independent of the underlying genetic cause. ### Considering clinical trials Clinical trials may provide access to investigational treatments, but benefits and risks are not yet fully known. Eligibility can depend on genetic findings, disease stage, retinal structure, age, and prior treatments. Natural-history research, including the active ABCA4 study NCT01736293, also helps researchers understand how Stargardt disease changes over time.

Outlook: The visual prognosis for Stargardt disease is generally poor regarding central vision, with most patients eventually progressing to legal blindness (visual acuity of 20/200 or worse). However, peripheral vision is typically preserved, allowing patients to maintain independent mobility. The rate of progression and final visual outcome are highly dependent on the age of onset, with earlier onset correlating with more severe and rapid vision loss. Quality of life can be significantly impacted, but low vision rehabilitation and adaptive devices can help patients manage daily activities.

Epidemiology: Stargardt disease is the most common form of inherited juvenile macular degeneration. The estimated prevalence is approximately 1 in 8,000 to 1 in 10,000 individuals worldwide. It affects males and females equally, and no specific race predilection has been noted, though the highest prevalence is often reported in populations of European descent.

Selected references: 1. Al-Khuzaei S, Broadgate S, Foster CR, Shah M, Yu J, Downes SM, Halford S. An Overview of the Genetics of ABCA4 Retinopathies, an Evolving Story. Genes (Basel). 2021;12(8):1241. PMID: 34440414 2. Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2017;101(1):25-30. PMID: 27493061 3. Huang D, Heath Jeffery RC, Aung-Htut MT, et al. Stargardt disease and progress in therapeutic strategies. Ophthalmic Genet. 2022;43(1):1-26. PMID: 34515594 4. Strauss RW, Ho A, Muñoz B, et al. The natural history of the progression of atrophy secondary to Stargardt disease (ProgStar) studies. Ophthalmology. 2016;123(4):817-828. PMID: 26783096 5. Kohli P, Patel BC. Stargardt Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 30725985